3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Ovarian Neoplasms
3
Lymphoma, Large B-Cell, Diffuse
2
Lung Neoplasms
2
Hodgkin Disease
2
Fallopian Tube Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Waldenstrom Macroglobulinemia
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Prolymphocytic, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Glioma
1
Estrogen Receptor and/or Progesterone Receptor Positive
1
Endometrial Neoplasms
1
Diffuse Intrinsic Pontine Glioma
1
Calcinosis
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Temozolomide
10
Radiotherapy
10
Bevacizumab
6
Everolimus
5
ribociclib
3
Radiation
3
Panobinostat
3
Dasatinib
3
Valproic Acid
2
TIC10 compound
2
Re-Irradiation
2
Nivolumab
2
Mebendazole
2
Irinotecan
2
Gemcitabine
2
GDC-0084
2
Etoposide
2
Erlotinib Hydrochloride
2
Diphtheria-Tetanus Vaccine
2
Cyclophosphamide
2
Cilengitide
2
Cetuximab
2
vandetanib
1
tovorafenib
1
temsirolimus
1
spartalizumab
1
sargramostim
1
reolysin
1
pembrolizumab
1
ovex
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Diffuse Intrinsic Pontine Glioma
×
Pharmacogenomic Variants
×
Clear all
NCT01165333
2026-03-16
CILENT
Centre Oscar Lambret
Phase 1
Completed
32 enrolled